Brainstorm Cell Therapeutics Inc.

NasdaqCM:BCLI 주식 보고서

시가총액: US$7.1m

Brainstorm Cell Therapeutics 미래 성장

Future 기준 확인 0/6

Brainstorm Cell Therapeutics은 연간 수입과 매출이 각각 15.9%와 91.5% 증가할 것으로 예상되고 EPS는 연간 26.4%만큼 증가할 것으로 예상됩니다.

주요 정보

15.9%

수익 성장률

26.4%

EPS 성장률

Biotechs 수익 성장28.3%
매출 성장률91.5%
향후 자기자본 수익률n/a
애널리스트 커버리지

Low

마지막 업데이트12 Nov 2024

최근 미래 성장 업데이트

Recent updates

Brainstorm Cell Therapeutics: Upcoming BLA In ALS

Aug 21

BrainStorm Cell Therapeutics Q2 2022 Earnings Preview

Aug 12

Is Brainstorm Cell Therapeutics (NASDAQ:BCLI) In A Good Position To Invest In Growth?

Aug 05
Is Brainstorm Cell Therapeutics (NASDAQ:BCLI) In A Good Position To Invest In Growth?

Is Brainstorm Cell Therapeutics (NASDAQ:BCLI) In A Good Position To Invest In Growth?

Mar 22
Is Brainstorm Cell Therapeutics (NASDAQ:BCLI) In A Good Position To Invest In Growth?

Is Brainstorm Cell Therapeutics (NASDAQ:BCLI) In A Good Position To Invest In Growth?

Nov 26
Is Brainstorm Cell Therapeutics (NASDAQ:BCLI) In A Good Position To Invest In Growth?

Brainstorm Cell Therapeutics: MSC-NTF Cell Therapy Shows Mid-Stage Promise In PMS

May 30

Is Brainstorm Cell Therapeutics (NASDAQ:BCLI) In A Good Position To Deliver On Growth Plans?

May 02
Is Brainstorm Cell Therapeutics (NASDAQ:BCLI) In A Good Position To Deliver On Growth Plans?

BrainStorm Cell Therapeutics EPS beats by $0.07

Apr 26

Who Has Been Buying Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Shares?

Feb 21
Who Has Been Buying Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Shares?

BrainStorm Cell Therapeutics EPS misses by $0.18

Feb 04

Here's Why We're Watching Brainstorm Cell Therapeutics' (NASDAQ:BCLI) Cash Burn Situation

Jan 17
Here's Why We're Watching Brainstorm Cell Therapeutics' (NASDAQ:BCLI) Cash Burn Situation

BrainStorm completes dosing in Phase 2 MS Study

Dec 18

BrainStorm launches NurOwn Expanded Access Program

Dec 14

What Percentage Of Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Shares Do Insiders Own?

Dec 13
What Percentage Of Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Shares Do Insiders Own?

BrainStorm's NurOwn flunks in late-stage ALS study

Nov 17

수익 및 매출 성장 예측

NasdaqCM:BCLI - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜수익수익잉여 현금 흐름작전 현금평균 애널리스트 수
12/31/2026N/A-26-44N/A3
12/31/2025N/A-25-13-123
12/31/2024N/A-14-14-143
9/30/2024N/A-14-11-11N/A
6/30/2024N/A-13-14-14N/A
3/31/2024N/A-16-20-20N/A
12/31/2023N/A-17-20-20N/A
9/30/2023N/A-17-22-22N/A
6/30/2023N/A-22-20-20N/A
3/31/2023N/A-24-20-20N/A
12/31/2022N/A-24-19-19N/A
9/30/2022N/A-25-20-20N/A
6/30/2022N/A-24-22-22N/A
3/31/2022N/A-23-21-21N/A
12/31/2021N/A-24-27-26N/A
9/30/2021N/A-30-29-28N/A
6/30/2021N/A-29-29-29N/A
3/31/2021N/A-30-30-29N/A
12/31/2020N/A-32-36-35N/A
9/30/2020N/A-28-31-31N/A
6/30/2020N/A-29-28-28N/A
3/31/2020N/A-26-26-25N/A
12/31/2019N/A-23-12-11N/A
9/30/2019N/A-21-12-12N/A
6/30/2019N/A-18-15-15N/A
3/31/2019N/A-17-11-11N/A
12/31/2018N/A-14-13-12N/A
9/30/2018N/A-8-12-12N/A
6/30/2018N/A-8N/A-1N/A
3/31/2018N/A-5N/A-3N/A
12/31/2017N/A-5N/A-2N/A
9/30/2017N/A-6N/A-1N/A
6/30/2017N/A-5N/A-5N/A
3/31/2017N/A-5N/A-5N/A
12/31/2016N/A-5N/A-6N/A
9/30/2016N/A-6N/A-6N/A
6/30/2016N/A-7N/A-8N/A
3/31/2016N/A-8N/A-8N/A
12/31/2015N/A-8N/A-7N/A
9/30/2015N/A-10N/A-8N/A
6/30/2015N/A-10N/A-7N/A
3/31/2015N/A-9N/A-6N/A
12/31/2014N/A-9N/A-4N/A
9/30/2014N/A-8N/A-4N/A
6/30/2014N/A-6N/A-4N/A
3/31/2014N/A-6N/A-4N/A

애널리스트 미래 성장 예측

수입 대 저축률: BCLI 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 vs 시장: BCLI 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

고성장 수익: BCLI 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 대 시장: BCLI 은(는) 내년에 수익이 없을 것으로 예상됩니다.

고성장 수익: BCLI 은(는) 내년에 수익이 없을 것으로 예상됩니다.


주당 순이익 성장 예측


미래 자기자본 수익률

미래 ROE: BCLI 의 자기자본수익률이 3년 내에 높을 것으로 예상되는지 판단하기에는 데이터가 부족합니다.


성장 기업 발견